Skip to content

SAB Biotherapeutics, Inc.

SABS SABSW

CIK 0001833214 · Biological Products, (No Diagnostic Substances) · Nasdaq, Nasdaq

  • Big Cypress Acquisition Corp. (until 2021-10-22)
← back to feed
Revenue (TTM)
$2.56M
−100.0% YoY Q1 May 2026
Net Income (TTM)
$11.27M
+138.9% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.21
+78.5% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-2,076.9%
Q1 May 2026
Net Margin
440.0%
Q1 May 2026
Free Cash Flow (TTM)
−$36.92M
Q1 May 2026
Cash
$20.52M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
76.46M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings